IL33 and benign prostatic hyperplasia: In addition to studies conducted in Chinese populations (14), research from a Canadian cohort has demonstrated that IL-33 expression is significantly reduced in metastatic prostate cancer (PCa) compared to primary PCa or benign prostatic hyperplasia (BPH) (15).